209 related articles for article (PubMed ID: 32824729)
1. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Schöppe J; Ehrenmann J; Klenk C; Rucktooa P; Schütz M; Doré AS; Plückthun A
Nat Commun; 2019 Jan; 10(1):17. PubMed ID: 30604743
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Biological Evaluation of Aprepitant Based
Halik PK; Koźmiński P; Matalińska J; Lipiński PFJ; Misicka A; Gniazdowska E
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335981
[TBL] [Abstract][Full Text] [Related]
4. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
5. Novel NK1R-Targeted
Matalińska J; Kosińska K; Halik PK; Koźmiński P; Lipiński PFJ; Gniazdowska E; Misicka A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163139
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
7. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
[TBL] [Abstract][Full Text] [Related]
9. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
[TBL] [Abstract][Full Text] [Related]
10. GPCR large-amplitude dynamics by
Pan B; Liu D; Yang L; Wüthrich K
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2122682119. PubMed ID: 35377814
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
Matalińska J; Świć A; Lipiński P; Misicka A
Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis.
Liu BK; Jin XW; Lu HZ; Zhang X; Zhao ZH; Shao Y
Inflammation; 2019 Feb; 42(1):246-254. PubMed ID: 30196377
[TBL] [Abstract][Full Text] [Related]
14. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
[TBL] [Abstract][Full Text] [Related]
16. Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography.
Chen S; Lu M; Liu D; Yang L; Yi C; Ma L; Zhang H; Liu Q; Frimurer TM; Wang MW; Schwartz TW; Stevens RC; Wu B; Wüthrich K; Zhao Q
Nat Commun; 2019 Feb; 10(1):638. PubMed ID: 30733446
[TBL] [Abstract][Full Text] [Related]
17. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
19. The neuropeptide substance P regulates aldosterone secretion in human adrenals.
Wils J; Duparc C; Cailleux AF; Lopez AG; Guiheneuf C; Boutelet I; Boyer HG; Dubessy C; Cherifi S; Cauliez B; Gobet F; Defortescu G; Ménard JF; Louiset E; Lefebvre H
Nat Commun; 2020 May; 11(1):2673. PubMed ID: 32471973
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
